{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:42:41Z","timestamp":1788979361134,"version":"build-2803163510"},"reference-count":149,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.autrev.2026.104122","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:11:35Z","timestamp":1781460695000},"page":"104122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unraveling giant cell arteritis: From immunopathology to emerging targeted therapies (2026 update)"],"prefix":"10.1016","volume":"25","author":[{"given":"Cory","family":"Cayrou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Gallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Fauchais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Bouanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Parreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003824","article-title":"Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register","volume":"10","author":"Fern\u00e1ndez-Lozano","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11910-024-01386-3","article-title":"The set up and the triggers: an update on the risk factors for giant cell arteritis","volume":"25","author":"Labowsky","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.semarthrit.2018.07.001","article-title":"Smoking as a risk factor for giant cell arteritis: a systematic review and meta-analysis","volume":"48","author":"Brennan","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/keu331","article-title":"Body mass index and the risk of giant cell arteritis\u2014results from a prospective study","volume":"54","author":"Jakobsson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.autrev.2026.104122_bb0025","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1093\/rheumatology\/keaa080","article-title":"Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis","volume":"59","author":"Wadstr\u00f6m","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-021-02450-w","article-title":"A meta-analysis of the epidemiology of giant cell arteritis across time and space","volume":"23","author":"Li","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1592","key":"10.1016\/j.autrev.2026.104122_bb0035","first-page":"14","article-title":"Epidemiology of giant cell arteritis in Waikato, Aotearoa New Zealand","volume":"137","author":"van Dantzig","year":"2024","journal-title":"N Z Med J"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/03009742.2014.982701","article-title":"The incidence of giant cell arteritis in Olmsted County Minnesota, over a sixty year period 1950\u20132009","volume":"44","author":"Chandran","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104122_bb0045","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.semarthrit.2020.07.005","article-title":"Incidence and prevalence of Giant cell arteritis and polymyalgia Rheumatica: a systematic literature review","volume":"50","author":"Sharma","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/bjo.2009.177220","article-title":"Giant cell arteritis in Asians: a comparative study","volume":"95","author":"Pereira","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104122_bb0055","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of Giant cell arteritis and polymyalgia Rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajhg.2016.11.013","article-title":"A genome-wide association study identifies risk alleles in plasminogen and P4HA2 associated with giant cell arteritis","volume":"100","author":"Carmona","year":"2017","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1016\/j.autrev.2026.104122_bb0065","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1002\/art.22218","article-title":"Interleukin-10 promoter polymorphisms in giant cell arteritis","volume":"54","author":"Boiardi","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0070","first-page":"179","article-title":"IL-6 promoter polymorphism at position \u2212174 modulates the phenotypic expression of polymyalgia Rheumatica in biopsy-proven giant cell arteritis","volume":"20","author":"Gonzalez-Gay","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/rheumatology\/ket231","article-title":"Genetic component of giant cell arteritis","volume":"53","author":"Carmona","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13148-019-0632-2","article-title":"The emerging role of epigenetics in human autoimmune disorders","volume":"11","author":"Mazzone","year":"2019","journal-title":"Clin Epigenetics"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0085","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/annrheumdis-2014-207116","article-title":"DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis","volume":"75","author":"Coit","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/art.43358","article-title":"Genome-wide DNA methylation study reveals specific signatures in the affected arterial tissue of patients with giant cell arteritis","volume":"78","author":"Borrego-Yaniz","year":"2026","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104122_bb0095","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/annrheumdis-2015-207846","article-title":"MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis","volume":"75","author":"Croci","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103739","article-title":"Current state of epigenetics in giant cell arteritis: focus on microRNA dysregulation","volume":"24","author":"Bolha","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"19 Pt 2","key":"10.1016\/j.autrev.2026.104122_bb0105","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0755-4982(04)98939-7","article-title":"Is Giant cell arteritis an infectious disease? Biological and Epidemiological Evidence","volume":"33","author":"Duhaut","year":"2004","journal-title":"Presse Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0110","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/annrheumdis-2016-210152","article-title":"Infections and the risk of incident giant cell arteritis: a population-based, case-control study","volume":"76","author":"Rhee","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2026.104122_bb0115","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00296-025-06004-0","article-title":"Seasonality and latitude as linked environmental factors in giant cell arteritis incidence: a systematic review and meta-analysis","volume":"45","author":"Dhrif","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104122_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1196\/annals.1358.023","article-title":"Vascular dendritic cells in giant cell arteritis","volume":"1062","author":"Weyand","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"10.1016\/j.autrev.2026.104122_bb0125","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamaneurol.2015.2101","article-title":"Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis","volume":"72","author":"Nagel","year":"2015","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.semarthrit.2017.02.005","article-title":"No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis","volume":"47","author":"Muratore","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yexmp.2015.12.007","article-title":"VZV, temporal arteritis, and clinical practice: false positive Immunohistochemical detection due to antibody cross-reactivity","volume":"100","author":"Pisapia","year":"2016","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4081\/reumatismo.2013.36","article-title":"Giant cell arteritis associated with chronic active Epstein-Barr virus infection","volume":"65","author":"Giardina","year":"2013","journal-title":"Reumatismo"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1309\/2996TT2CTLTKN0KT","article-title":"High prevalence of herpes simplex virus DNA in temporal arteritis biopsy specimens","volume":"123","author":"Powers","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0150","first-page":"112","article-title":"Synchronous variations of the incidence of temporal arteritis and polymyalgia Rheumatica in different regions of Denmark; association with epidemics of mycoplasma pneumoniae infection","volume":"23","author":"Elling","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104122_bb0155","first-page":"37","article-title":"Reinfection with Chlamydia pneumoniae may induce isolated and systemic Vasculitis in small and large vessels","volume":"104","author":"Ljungstr\u00f6m","year":"1997","journal-title":"Scand J Infect Dis Suppl"},{"issue":"7","key":"10.1016\/j.autrev.2026.104122_bb0160","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1529-0131(200007)43:7<1543::AID-ANR19>3.0.CO;2-8","article-title":"Detection of Chlamydia pneumoniae in giant cell Vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells","volume":"43","author":"Wagner","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0165","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cardiores.2007.06.020","article-title":"The dynamic vasa Vasorum","volume":"75","author":"Ritman","year":"2007","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1084\/jem.20030850","article-title":"Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis","volume":"199","author":"Ma-Krupa","year":"2004","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0175","doi-asserted-by":"crossref","first-page":"36419","DOI":"10.1038\/s41598-025-20436-5","article-title":"Mature CD209+CD83+CCR7+ dendritic cells infiltrate the arterial wall in giant cell arteritis and derive from in-situ monocyte differentiation","volume":"15","author":"Ramon","year":"2025","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0180","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.108.185777","article-title":"Toll-like receptors 4 and 5 induce distinct types of Vasculitis","volume":"104","author":"Deng","year":"2009","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0185","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clim.2005.02.009","article-title":"Toll-like receptors in giant cell arteritis","volume":"115","author":"Ma-Krupa","year":"2005","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104122_bb0190","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.108.789172","article-title":"Vessel-specific toll-like receptor profiles in human medium and large arteries","volume":"118","author":"Pryshchep","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0195","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s10020-025-01390-4","article-title":"Increased expression of toll-like receptors and associated Alarmins in temporal arteries of patients with Giant cell arteritis","volume":"31","author":"Seidlberger","year":"2025","journal-title":"Mol Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0200","first-page":"1925","article-title":"Interferon-gamma-producing T cells in giant cell Vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology","volume":"148","author":"Wagner","year":"1996","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0205","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCRESAHA.118.313206","article-title":"MMP (matrix metalloprotease)-9-producing monocytes enable T cells to invade the vessel wall and cause vasculitis","volume":"123","author":"Watanabe","year":"2018","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0210","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2008.10.011","article-title":"IRF-4-binding protein inhibits interleukin-17 and Interleukin-21 production by controlling the activity of IRF-4 transcription factor","volume":"29","author":"Chen","year":"2008","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.autrev.2026.104122_bb0215","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-cell responses in giant cell arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"issue":"7395","key":"10.1016\/j.autrev.2026.104122_bb0220","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10957","article-title":"Pathogen-induced human TH17 cells produce IFN-\u03b3 or IL-10 and are regulated by IL-1\u03b2","volume":"484","author":"Zielinski","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104122_bb0225","article-title":"The IL-17 pathway as a target in giant cell arteritis","volume":"14","author":"Zeisbrich","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104122_bb0230","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2016-210070","article-title":"An expanded population of pathogenic regulatory T-cells in giant cell arteritis is abrogated by IL-6 blockade therapy","volume":"76","author":"Miyabe","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0235","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.4049\/jimmunol.166.4.2768","article-title":"Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release","volume":"166","author":"Abdelilah","year":"2001","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104122_bb0240","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/eji.201041125","article-title":"IL-9 is important for T cell activation and differentiation in autoimmune inflammation of the central nervous system","volume":"41","author":"Li","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2026.104122_bb0245","series-title":"Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis","author":"Ciccia","year":"2026"},{"key":"10.1016\/j.autrev.2026.104122_bb0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2016.05.008","article-title":"Involvement and prognosis value of CD8(+) T cells in giant cell arteritis","volume":"72","author":"Samson","year":"2016","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0255","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/annrheumdis-2016-209217","article-title":"Ectopic expression of CXCL13, BAFF, APRIL and LT-\u03b2 is associated with artery tertiary lymphoid organs in giant cell arteritis","volume":"76","author":"Ciccia","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0260","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jbspin.2016.07.005","article-title":"Pro-inflammatory and anti-inflammatory T cells in giant cell arteritis","volume":"84","author":"Watanabe","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2026.104122_bb0265","series-title":"A distinct macrophage subset mediating tissue destruction and neovascularization in giant cell arteritis: implication of the YKL-40\/interleukin-13 receptor \u03912 axis","author":"van Sleen","year":"2026"},{"issue":"9","key":"10.1016\/j.autrev.2026.104122_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1164","article-title":"Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis","volume":"9","author":"Jiemy","year":"2020","journal-title":"Clin Transl Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0275","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/CIRCULATIONAHA.104.520114","article-title":"Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling","volume":"112","author":"Rodr\u00edguez-Pla","year":"2005","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.autrev.2026.104122_bb0280","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1172\/JCI118959","article-title":"Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis","volume":"98","author":"Weyand","year":"1996","journal-title":"J Clin Invest"},{"issue":"15","key":"10.1016\/j.autrev.2026.104122_bb0285","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1042\/CS20220531","article-title":"M1\/M2 macrophages and their overlaps \u2013 myth or reality?","volume":"137","author":"Strizova","year":"2023","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0290","first-page":"107","article-title":"An Immunohistochemical analysis of folate receptor beta expression and distribution in giant cell arteritis - a pilot study","volume":"6","author":"Albano-Aluquin","year":"2017","journal-title":"Am J Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104122_bb0295","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002368","article-title":"Description and validation of histological patterns and proposal of a dynamic model of inflammatory infiltration in Giant-cell arteritis","volume":"95","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2026.104122_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2021.151728","article-title":"An immunohistochemical analysis of fibroblasts in giant cell arteritis","volume":"52","author":"Parreau","year":"2021","journal-title":"Ann Diagn Pathol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104122_bb0305","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1093\/rheumatology\/keaf143","article-title":"Distinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritis","volume":"64","author":"Xu","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104122_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103151","article-title":"Neointimal myofibroblasts contribute to maintaining Th1\/Tc1 and Th17\/Tc17 inflammation in giant cell arteritis","volume":"142","author":"Greigert","year":"2024","journal-title":"J Autoimmun"},{"issue":"20","key":"10.1016\/j.autrev.2026.104122_bb0315","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153471","article-title":"Single-cell transcriptomics reveals skewed cellular communication and phenotypic shift in pulmonary artery remodeling","volume":"7","author":"Crnkovic","year":"2022","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.autrev.2026.104122_bb0320","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1161\/01.CIR.101.12.1362","article-title":"Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries","volume":"101","author":"Li","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0325","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0008-6363(03)00292-X","article-title":"Migration of adventitial myofibroblasts following vascular balloon injury: insights from in vivo gene transfer to rat carotid arteries","volume":"59","author":"Siow","year":"2003","journal-title":"Cardiovasc Res"},{"issue":"8","key":"10.1016\/j.autrev.2026.104122_bb0330","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-019-0512-5","article-title":"Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis","volume":"25","author":"Wirka","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0335","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bbrc.2006.11.073","article-title":"Adventitial fibroblasts are activated in the early stages of atherosclerosis in the apolipoprotein E knockout mouse","volume":"352","author":"Xu","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0340","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/1529-0131(199804)41:4<623::AID-ART9>3.0.CO;2-6","article-title":"Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in Giant cell arteritis","volume":"41","author":"Kaiser","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2026.104122_bb0345","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/ard.2007.070805","article-title":"Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis","volume":"67","author":"Lozano","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0350","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ard.2008.105692","article-title":"Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events","volume":"69","author":"Lozano","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104122_bb0355","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1136\/annrheumdis-2016-210792","article-title":"Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis","volume":"76","author":"Planas-Rigol","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0360","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.autrev.2017.02.006","article-title":"Molecular analysis of vascular smooth muscle cells from patients with Giant cell arteritis: targeting endothelin-1 receptor to control proliferation","volume":"16","author":"R\u00e9gent","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2026.104122_bb0365","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/art.30374","article-title":"Expression of Interleukin-32 in the inflamed arteries of patients with giant cell arteritis","volume":"63","author":"Ciccia","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104122_bb0370","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/acr.25354","article-title":"Altered plasma levels and tissue expression of fibroblast activation protein alpha in giant cell arteritis","volume":"76","author":"Xu","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0375","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf408","article-title":"Crosstalk between macrophages and fibroblasts contributes to inflammation and damage in giant cell arteritis","volume":"65","author":"Xu","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103574","article-title":"Current evidence on the role of fibroblasts in large-vessel vasculitides: from pathogenesis to therapeutics","volume":"23","author":"Xu","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104122_bb0385","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1016\/j.revmed.2019.03.084","article-title":"Fibroblaste adventitiel, un acteur important de l\u2019art\u00e9rite \u00e0 cellules g\u00e9antes","volume":"40","author":"Parreau","year":"2019","journal-title":"Rev Med Interne"},{"issue":"9","key":"10.1016\/j.autrev.2026.104122_bb0390","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1111\/jcmm.16524","article-title":"Macrophage-derived exosomes mediate silica-induced pulmonary fibrosis by activating fibroblast in an endoplasmic reticulum stress-dependent manner","volume":"25","author":"Qin","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"399","key":"10.1016\/j.autrev.2026.104122_bb0395","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3322","article-title":"The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway","volume":"9","author":"Wen","year":"2017","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104122_bb0400","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1007\/s10792-023-02829-5","article-title":"Distinguishing laboratory characteristics in Giant cell arteritis: a real-world retrospective cohort study","volume":"43","author":"Goel","year":"2023","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.autrev.2026.104122_bb0405","article-title":"Effects of systemically administered hydrocortisone on the human immunome","volume":"6","author":"Olnes","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0410","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCRESAHA.114.301374","article-title":"Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression","volume":"114","author":"Nadkarni","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.autrev.2026.104122_bb0415","doi-asserted-by":"crossref","unstructured":"Wang, L.; Ai, Z.; Khoyratty, T.; Zec, K.; Eames, H. L.; van Grinsven, E.; Hudak, A.; Morris, S.; Ahern, D.; Monaco, C.; Eruslanov, E. B.; Luqmani, R.; Udalova, I. A. ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies. JCI Insight 5 (20), e139163. doi:https:\/\/doi.org\/10.1172\/jci.insight.139163.","DOI":"10.1172\/jci.insight.139163"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0420","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.1660","article-title":"Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis","volume":"204","author":"Foell","year":"2004","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0425","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.084947","article-title":"Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss","volume":"68","author":"Chatelain","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0430","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/keab505","article-title":"Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines","volume":"61","author":"Palamidas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.autrev.2026.104122_bb0435","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3390\/biom15111586","article-title":"The type I interferon axis in systemic autoimmune diseases: from molecular pathways to targeted therapy","volume":"15","author":"Ishihara","year":"2025","journal-title":"Biomolecules"},{"issue":"18","key":"10.1016\/j.autrev.2026.104122_bb0440","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2026.104122_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102796","article-title":"Interferon signature in giant cell arteritis aortitis","volume":"127","author":"Vieira","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104122_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1197293","article-title":"Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients","volume":"14","author":"van Nieuwland","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0455","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/cei\/uxae085","article-title":"Investigating interferon type I responses in patients with suspected giant cell arteritis and polymyalgia rheumatica","volume":"218","author":"van Nieuwland","year":"2024","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0460","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2021-220955","article-title":"Novel aspects of regulatory T cell dysfunction as a therapeutic target in Giant cell arteritis","volume":"81","author":"Adriawan","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2026.104122_bb0465","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1136\/annrheumdis-2012-201660","article-title":"NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica","volume":"72","author":"Dejaco","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104122_bb0470","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1172\/JCI84181","article-title":"NADPH oxidase deficiency underlies dysfunction of aged CD8+ tregs","volume":"126","author":"Wen","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0475","doi-asserted-by":"crossref","first-page":"E970","DOI":"10.1073\/pnas.1616848114","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0480","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/rheumatology\/keab337","article-title":"Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case\u2013control and exploratory study","volume":"61","author":"Papo","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0485","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard-2023-224933","article-title":"Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu\u2019s arteritis, ANCA-associated vasculitis and giant cell arteritis","volume":"83","author":"Gutierrez-Rodrigues","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0490","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/art.42738","article-title":"Association of somatic TET2 mutations with giant cell arteritis","volume":"76","author":"Robinette","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0495","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004694","article-title":"Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis","volume":"10","author":"Guedon","year":"2024","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.autrev.2026.104122_bb0500","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41577-023-00843-3","article-title":"Clonal haematopoiesis and dysregulation of the immune system","volume":"23","author":"Belizaire","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0505","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1172\/JCI95148","article-title":"Mechanisms and functions of cellular senescence","volume":"128","author":"Herranz","year":"2018","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0510","article-title":"IL-6-STAT3 signaling and premature senescence","volume":"2","author":"Kojima","year":"2013","journal-title":"JAKSTAT"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0515","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10522-014-9529-9","article-title":"Senescent cells: SASPected drivers of age-related pathologies","volume":"15","author":"Ovadya","year":"2014","journal-title":"Biogerontology"},{"key":"10.1016\/j.autrev.2026.104122_bb0520","series-title":"Indication of activated senescence pathways in the temporal arteries of patients with giant cell arteritis","author":"Jiemy","year":"2026"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0525","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/ard-2023-224467","article-title":"Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways","volume":"83","author":"Veroutis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104122_bb0530","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0535","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0540","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104122_bb0545","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0550","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/rheumatology\/keae459","article-title":"The use of intravenous methylprednisolone in giant cell arteritis: a population-based study","volume":"64","author":"Henningson","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2026.104122_bb0555","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00296-023-05321-6","article-title":"Oral or pulse glucocorticoid use at the onset of giant cell arteritis and its influence on the risk of relapse: a retrospective study","volume":"43","author":"Trives-Folguera","year":"2023","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0560","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/S2665-9913(25)00321-2","article-title":"Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits","volume":"8","author":"Schenning","year":"2026","journal-title":"The Lancet Rheumatology"},{"issue":"10031","key":"10.1016\/j.autrev.2026.104122_bb0565","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104122_bb0570","series-title":"Seminars in arthritis and rheumatism","first-page":"152955","article-title":"Is there a window of opportunity in the treatment of giant cell arteritis with tocilizumab? Multicenter study of 471 patients","volume":"78","author":"Mart\u00edn-Guti\u00e9rrez","year":"2026"},{"issue":"8","key":"10.1016\/j.autrev.2026.104122_bb0575","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104122_bb0580","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3899\/jrheum.180429","article-title":"Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study","volume":"46","author":"Koster","year":"2019","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0585","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104122_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152192","article-title":"Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis","volume":"60","author":"Lavergne","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0595","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104122_bb0600","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104122_bb0605","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320975233","article-title":"Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis","volume":"11","author":"Wu","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.autrev.2026.104122_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152166","article-title":"Efficacy and safety of leflunomide in the management of large vessel vasculitis: a systematic review and metaanalysis of cohort studies","volume":"59","author":"Narv\u00e1ez","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0615","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009742.2019.1575980","article-title":"Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival","volume":"48","author":"Tengesdal","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104122_bb0620","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-25-1129","article-title":"Systematic review and meta-analysis for JCS 2026 guideline on management of large-vessel vasculitis","author":"Shirai","year":"2026","journal-title":"Circ J"},{"key":"10.1016\/j.autrev.2026.104122_bb0625","article-title":"Mycophenolate mofetil in giant cell arteritis","volume":"10","author":"Pankow","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0630","article-title":"Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis","volume":"4","author":"Karabayas","year":"2020","journal-title":"Rheumatol Adv Pract"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0635","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"De Silva","year":"1986","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104122_bb0640","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.autrev.2018.01.016","article-title":"New use for an old treatment: hydroxychloroquine as a potential treatment for systemic vasculitis","volume":"17","author":"Casian","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"7\u20138","key":"10.1016\/j.autrev.2026.104122_bb0645","first-page":"485","article-title":"Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients","volume":"61","author":"Le Guennec","year":"1994","journal-title":"Rev Rhum Ed Fr"},{"issue":"20","key":"10.1016\/j.autrev.2026.104122_bb0650","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0655","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-024-03314-9","article-title":"Effectiveness of Janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature","volume":"26","author":"Loricera","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0660","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-023-03177-6","article-title":"A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis","volume":"25","author":"Schmidt","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0665","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40744-020-00227-2","article-title":"A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of sirukumab in the treatment of giant cell arteritis","volume":"7","author":"Schmidt","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0670","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the treatment of giant cell arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104122_bb0675","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2026.104122_bb0680","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2016-209351","article-title":"Ustekinumab for the treatment of refractory Giant cell arteritis","volume":"75","author":"Conway","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104122_bb0685","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ard.2026.01.009","article-title":"A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis","volume":"85","author":"Makhzoum","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104122_bb0690","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthrit Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104122_bb0695","doi-asserted-by":"crossref","first-page":"125","DOI":"10.55563\/clinexprheumatol\/l0hd9v","article-title":"An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis","volume":"39 Suppl 129","author":"Rossi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0700","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0705","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13075-025-03493-z","article-title":"Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"27","author":"de Boysson","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.autrev.2026.104122_bb0710","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104122_bb0715","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/ard.2005.036533","article-title":"Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis","volume":"64","author":"Bhatia","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104122_bb0720","article-title":"Rituximab fails to treat giant cell arteritis in a patient with ACPA-positive rheumatoid arthritis","volume":"5","author":"Mulhearn","year":"2021","journal-title":"Rheumatol Adv Pract"},{"issue":"9","key":"10.1016\/j.autrev.2026.104122_bb0725","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.autrev.2026.104122_bb0730","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.autrev.2026.104122_bb0735","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104122_bb0740","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104122_bb0745","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s13075-014-0487-z","article-title":"Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling","volume":"16","author":"Ly","year":"2014","journal-title":"Arthritis Res Ther"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:01:25Z","timestamp":1786071685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":149,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1568997226001369"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104122","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling giant cell arteritis: From immunopathology to emerging targeted therapies (2026 update)","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104122"}}